Acceleron Pharma Profit Margin

The latest profit margin for XLRN is -226.01% as of September 2021. That compares with -124.73% in the prior-year period — down 81.2% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Acceleron Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, XLRN's profit margin moved from -124.73% to -226.01% — a 81.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acceleron Pharma's valuation or profitability profile.

Against Healthcare companies, XLRN currently prints -226.01% for profit margin, while the sector average sits near 14.34%. That is roughly 1675.5% below the sector mean. Large gaps often invite a closer look at Acceleron Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Acceleron Pharma converts resources into returns. At -226.01%, XLRN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -124.73% in the prior-year period — down 81.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XLRN's profit margin (-226.01%), review year-over-year change from -124.73%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.